Source Endpoints News: One of Novartis’ top late-stage candidates for multiple sclerosis is now under review on both sides of the 
Atlantic.
Having stoked enthusiasm for siponimod through a solid Phase III data package, the Swiss drugmaker traded in a priority review voucher at the FDA for an expedited action date around March of next year. The EMA decision, meanwhile, will likely come in late 2019.
If Novartis appears upbeat, it’s for obvious reasons. Read on.